Leveraging plant-derived nanovesicles for advanced nucleic acid-based gene therapy

Area of Science:

• Biotechnology and Genetic Engineering
• Nanomedicine and Drug Delivery Systems

Background:

• Gene therapy is evolving beyond direct gene repair for genetic disorders.
• Nucleic acid therapies (mRNA, miRNA, siRNA, DNA) modulate protein expression without altering genetic sequences.

Purpose of the Study:

• To review the innovative use of plant-derived nanovesicles (PDNVs) as a delivery system for nucleic acid therapies.
• To highlight PDNVs' potential in enhancing the stability, bioavailability, specificity, and efficacy of therapeutic nucleic acids.

Main Methods:

• Review of current literature on plant-derived nanovesicles (PDNVs).
• Analysis of PDNV properties and their application in delivering nucleic acid-based therapeutics.
• Examination of PDNVs' role in overcoming limitations of conventional gene therapy delivery methods.

Main Results:

• PDNVs enhance the stability and bioavailability of therapeutic nucleic acids.
• PDNVs improve the specificity and efficacy of nucleic acid therapies in targeted applications.
• PDNVs show potential for treating diseases such as cancer and inflammatory conditions.

Conclusions:

• Plant-derived nanovesicles (PDNVs) represent a promising advancement in gene therapy delivery.
• PDNV-based nucleic acid therapies offer a transformative potential for treating genetic and other diseases.
• This approach expands the scope of gene therapy by enabling functional genetic material delivery without altering the genetic sequence.